PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of |
On January 4, 2017, Paratek Pharmaceuticals, Inc. (the Company)
announced several leadership promotions, including the promotion
of Evan Loh, age 57, to President, Chief Operating Officer and
Chief Medical Officer of the Company, effective January 1, 2017.
Prior to the promotion, Dr. Loh served as the Companys President
and Chief Medical Officer since October 2014. Dr. Loh was
appointed President of the Company in June 2014 and Chief Medical
Officer in June 2012 and was the Chairman of the Board of
Directors of the Company from June 2012 to June 2014. From
October 2009 to January 2012, Dr. Loh served as Senior Vice
President, Development and Strategic Operations, Worldwide
Research and Development, at Pfizer Inc. From January 2007 to
October 2009, Dr. Loh was Vice President, Clinical Research
Development at Wyeth. He is the 2006 recipient of the Heroes of
Chemistry Award from the American Chemical Society for his
leadership role at Wyeth in the clinical development of Tygacil.
He currently serves as a member of the board of directors of
Nivalis Therapeutics, Inc. Dr. Loh has served as a faculty member
at both Harvard Medical School and the University of Pennsylvania
School of Medicine. Dr. Loh received his A.B. from Harvard
College and his M.D. from Harvard Medical School. He completed
his Internal Medicine and Cardiovascular fellowship training at
Brigham and Womens Hospital.
Dr. Loh continues to be employed under an employment agreement
with the Company entered into on February 4, 2015, which is filed
as an exhibit to the Companys 10-K for the year ended December
31, 2014. Dr. Loh does not have any family relationship with any
of the directors or executive officers of the Company. Dr. Loh is
not party to any related party transactions required to be
disclosed to Item 404(a) of Regulation S-K.
|
Item 7.01. |
Regulation FD Disclosure |
On January 4, 2017, the Company issued a press release relating
to the promotions of certain members of its executive leadership
team, including Dr. Loh, which is furnished herewith as Exhibit
99.1.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Number |
Description |
|
99.1 |
Press release issued by Paratek Pharmaceuticals, |
About PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK)
Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company’s sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company’s other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Recent Trading Information
PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) closed its last trading session up +0.20 at 15.60 with 209,117 shares trading hands.